Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Non-Current Liabilities: 2019-2023

Historic Total Non-Current Liabilities for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $442.9 million.

  • ADC Therapeutics' Total Non-Current Liabilities rose 30.49% to $442.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $442.9 million, marking a year-over-year increase of 30.49%. This contributed to the annual value of $341.5 million for FY2022, which is 9.65% down from last year.
  • Latest data reveals that ADC Therapeutics reported Total Non-Current Liabilities of $442.9 million as of Q3 2023, which was up 1.74% from $435.3 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Total Non-Current Liabilities ranged from a high of $442.9 million in Q3 2023 and a low of $112,904 during Q3 2020.
  • Over the past 3 years, ADC Therapeutics' median Total Non-Current Liabilities value was $348.4 million (recorded in 2022), while the average stood at $331.7 million.
  • As far as peak fluctuations go, ADC Therapeutics' Total Non-Current Liabilities soared by 346,540.51% in 2021, and later decreased by 13.28% in 2022.
  • Quarterly analysis of 5 years shows ADC Therapeutics' Total Non-Current Liabilities stood at $6.6 million in 2019, then reached $112,904 in 2020, then spiked by 346,540.51% to $377.9 million in 2021, then fell by 9.65% to $341.5 million in 2022, then spiked by 30.49% to $442.9 million in 2023.
  • Its Total Non-Current Liabilities stands at $442.9 million for Q3 2023, versus $435.3 million for Q2 2023 and $348.9 million for Q1 2023.